Ref. no Title | |
Biomarkers and Imaging | |
001 |
A metagenomics study of the elbow of psoriasis subjects and their healthy relatives |
Clinical phenotypes | |
002 |
Nail disorders in patients with Psoriasis vulgaris |
003 |
Psoriasis hidden in Gottron’ s papules |
Comorbidities | |
004 |
Characteristics of psoriasis in obese patients versus non-obese patients; a multicenter study |
005 |
Psoriasis and comorbidity |
006 |
Risk of periodontal disease in patients with chronic plaque psoriasis |
007 |
Splenomegaly and Psoriasis- A case report |
008 |
Psoriasis as predictor for cardiovascular and metabolic comorbidity in middle-aged women |
009 |
A Case of Concurrent Psoriasis and Vitiligo |
010 |
Successful long-term double disease control by adalimumab in a patient with psoriasis vulgaris and hidradenitis suppurativa |
011 |
Clinical and epidemiological caracterization of psoriasis and psoriatic arthritis on a multidisciplinary assesment model. |
012 |
Alcohol and Psoriasis- a Prospective Swedish Study |
013 |
¨Psoriasis and Cancer. Retrospective study in the Psoriasis sector of the Dermatology Service at Ramos Mejia Hospital¨ |
014 |
Hematological disorders in the patient with psoriatic arthritis treated with methotrexate and tumor necrosis alpha( TNFalpha) inhibitor |
015 |
The relationship between psoriasis, comorbidities, and depression onset: A nationwide observational control study |
Current and new therapeutic modalities | |
016 |
Efficacy of Adalimumab plus Methotrexate in Patients with Moderate to Severe Plaque Psoriasis |
018 |
Attainment of remission and minimal disease activity after starting methotrexate subcutaneous therap |
019 |
Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database |
020 |
Ixekizumab improves impact of genital psoriasis on sexual activity: Results from a Phase 3b study |
021 |
Dose optimization of Secukinumab in subjects with moderate to severe plaque psoriasis: OPTIMISE study |
022 |
Inhibition of anti-TNF-alpha cytokine in the treatment of psoriasis and the analysis of infectious complications |
023 |
Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis in Scandinavia |
024 |
First Patient-Reported Insights From a Multinational, Retrospective, Cross-Sectional Study of Real-World Experience of Psoriasis Patients |
Treated With Apremilast in Clinical Dermatology Practice( APPRECIATE) | |
025 |
Physician- and Patient-Reported Outcomes With Apremilast for Patients With Plaque Psoriasis During Routine Dermatology Care in |
Germany: A Second Interim Analysis | |
026 |
Improvements in Work Productivity With Up to 104 Weeks of Apremilast Monotherapy: Results From a Phase 3b, Randomized, Controlled |
Study in Biologic-Naive Subjects With Active Psoriatic Arthritis | |
027 |
Examining Disease Severity and Symptom Improvement With Patient and Physician Assessments: Results From a Phase IV Analysis of |
Apremilast in Patients With Moderate Plaque Psoriasis | |
028 |
Hemoglobin A1c and Weight Changes With Apremilast in Patients With Psoriasis and Psoriatic Arthritis: Pooled Laboratory Analysis of |
the Phase 3 ESTEEM and PALACE Trials | |
029 |
Canadian Humira Post-Marketing Observational Epidemiological Study Assessing the Effectiveness of Adalimumab vs Non-Biologic |
DMARDs in Psoriatic Arthritis( Complete-PsA): 12-Month Effectiveness Data | |
030 |
Secukinumab Efficacy in Patients with Active Psoriatic Arthritis: Meta-analysis of 4 Phase 3 Trials |
031 |
Impact of adalimumab vs. non-biologic treatments on skin outcomes of psoriatic arthritis patients: real-world data from the COMPLETE Study |
032 |
Ixekizumab Improves Nail and Skin Psoriasis through 52 Weeks of Treatment in Patients with Active Psoriatic Arthritis: Results from Two |
Randomized, Double-Blind, Phase 3, Clinical Trials( SPIRIT-P1 and SPIRIT-P2) | |
034 |
Ixekizumab Makes Therapeutic Thresholds Possible in Active Psoriatic Arthritis Patients: Results from SPIRIT Trials |
035 |
The macrophage modulator MP1032 shows safety and efficacy in a human phase IIa study for the treatment of moderate-to-severe plaque |
psoriasis | |
036 |
Secukinumab Improves Signs and Symptoms of Psoriatic Arthritis: Results from a Phase 3 Study, FUTURE 5 |
037 |
Incidence of Inflammatory Bowel Disease In Patients Treated With Secukinumab: Pooled Analysis of 21 Randomised Controlled Phase |
3 / 4 Clinical Trials of Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis | |
038 |
Analysis of the position of the fumaric acid esters in current European psoriasis guidelines |
039 |
Secukinumab Provides Rapid and Sustained Resolution of Enthesitis in Psoriatic Arthritis Patients: Pooled Analysis of Two Phase 3 Studies, |
FUTURE 2 and FUTURE 3 | |
041 |
Long-Term Safety of Adalimumab( HUMIRA) in Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated |
Analysis in 29,987 Patients Representing 56,951 Patient-years | |
042 |
Clinical response after guselkumab treatment among adalimumab PASI 90 non- responders: Results from the VOYAGE 1 and 2 trials |
043 |
Consistency of response by weight across subgroups of patients with psoriasis treated with guselkumab: Results from the VOYAGE 1 and |
2 trials | |
044 |
Impact of Clinical Specialty Setting on Disease Management in Patients with Psoriatic Arthritis |
045 |
Speed of response of guselkumab compared with adalimumab for the treatment of moderate-to-severe psoriasis: results through Week 24 |
from the phase 3, double-blinded, placebo- and active comparator-controlled VOYAGE 1 and VOYAGE 2 trials | |
046 |
Safety of Certolizumab Pegol over 48 Weeks in Chronic Plaque Psoriasis Phase 3 Trials |
047 |
Secukinumab Provides Sustained Minimal Disease Activity( MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis |
( DAPSA): 2-year Results from a Phase 3 Study | |